(Q36872678)

16 August 2017

1 reference

title

Preclinical and clinical properties of trimegestone: a potent and selective progestin (English)

1 reference

16 August 2017

Regine Sitruk-Ware

1

1 reference

16 August 2017

Ronald Bossemeyer

series ordinal

2

1 reference

16 August 2017

Phillipe Bouchard

series ordinal

3

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Gynecological Endocrinology

16 August 2017

published in

1 reference

16 August 2017

volume

23

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

310-319

1 reference

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Guidelines for the hormone treatment of women in the menopausal transition and beyond. Position statement by the Executive Committee of the International Menopause Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17beta-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

The pharmacological profile of a novel norpregnance progestin (trimegestone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Progestogens in hormonal replacement therapy: new molecules, risks, and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

The preclinical biology of a new potent and selective progestin: trimegestone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

In vitro characterization of trimegestone: a new potent and selective progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Conception and pharmacodynamic profile of drospirenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Pharmacological profile of progestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Anxiolytic Effect of Progesterone is Mediated by the Neurosteroid Allopregnanolone at Brain GABAA Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Hormone-replacement therapy and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Hormone replacement therapy and breast cancer: a qualitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

Estrogen plus progestin and the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590701267727

10.1080/09513590701267727

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference